Skin autofluorescence in the general population

This week, researchers from our department published a paper in the journal Diabetologia, on the measurement of skin autofluorescence to estimate the risk of developing type 2 diabetes, cardiovascular disease and mortality. The abstract of the paper is as follows:

Aims/hypothesis
Earlier studies have shown that skin autofluorescence measured with an AGE reader estimates the accumulation of AGEs in the skin, which increases with ageing and is associated with the metabolic syndrome and type 2 diabetes. In the present study, we examined whether the measurement of skin autofluorescence can predict 4 year risk of incident type 2 diabetes, cardiovascular disease (CVD) and mortality in the general population.
Methods
For this prospective analysis, we included 72,880 participants of the Dutch Lifelines Cohort Study, who underwent baseline investigations between 2007 and 2013, had validated baseline skin autofluorescence values available and were not known to have diabetes or CVD. Individuals were diagnosed with incident type 2 diabetes by self-report or by a fasting blood glucose ≥7.0 mmol/l or HbA1c ≥48 mmol/mol (≥6.5%) at follow-up. Participants were diagnosed as having incident CVD (myocardial infarction, coronary interventions, cerebrovascular accident, transient ischaemic attack, intermittent claudication or vascular surgery) by self-report. Mortality was ascertained using the Municipal Personal Records Database.
Results
After a median follow-up of 4 years (range 0.5–10 years), 1056 participants (1.4%) had developed type 2 diabetes, 1258 individuals (1.7%) were diagnosed with CVD, while 928 (1.3%) had died. Baseline skin autofluorescence was elevated in participants with incident type 2 diabetes and/or CVD and in those who had died (all p < 0.001), compared with individuals who survived and remained free of the two diseases. Skin autofluorescence predicted the development of type 2 diabetes, CVD and mortality, independent of several traditional risk factors, such as the metabolic syndrome, glucose and HbA1c.
Conclusions/interpretation
The non-invasive skin autofluorescence measurement is of clinical value for screening for future risk of type 2 diabetes, CVD and mortality, independent of glycaemic measures and the metabolic syndrome.

The full paper can be found online on the Diabetologia website:
https://link.springer.com/article/10.1007%2Fs00125-018-4769-x

HERE you can find a PowerPoint presentation explaining the concept of measuring skin autofluorescence and the results of the paper in more detail.

You may also find useful information on the website of the manufacturer of the AGe-reader:
www.diagnoptics.com

 

Publieke informatie over dit onderzoek vindt u o.a. op:

https://www.rtvnoord.nl/nieuws/201703/UMCG-apparaat-voorspelt-diabetes-en-overlijden

https://www.umcg.nl/NL/UMCG/Nieuws/Persberichten/Paginas/Slim-meetapparaatje-voorspelt-diabetes,-hart–en-vaatziekten-en-overlijden.aspx

https://www.dvhn.nl/groningen/Groningse-uitvinding-maakt-voorspellen-hartinfarct-nog-preciezer-23848890.html

https://www.telegraaf.nl/nieuws/2828789/apparaatje-voorspelt-diabetes-en-overlijden

https://www.newscientist.com/article/2186297-diabetes-can-be-diagnosed-by-simply-shining-a-light-on-your-skin/

http://pennstatehershey.adam.com/content.aspx?productId=35&gid=4300

 

Verhuizing Diabetescentrum 12 november 2018

Het Universitair DiabetesCentrum gaat binnenkort verhuizen. Vanaf 12 november vindt u in ons gebouw De Brug, op de begane grond. De gemakkelijkste ingang is nr. 47 aan de Oostersingel, zie de foto en de plattegrond. U loopt door de draaideur naar binnen, en vindt ons direct aan de linkerkant. Een bushalte is vlak in de buurt op de Oostersingel, of aan de hoofdingang van het UMCG.

Mensen die met de auto komen, parkeren het simpelst in garage Noord, en nemen dan trap of lift aan de noordelijke kant van de garage om pal naast het Diabetescentrum uit te komen. Ook uitermate comfortabel voor toegang voor mensen, die van een rolstoel afhankelijk zijn.

U vindt in de nieuwe locatie alle faciliteiten die belangrijk zijn voor uw zorg, en die u ook gewend was in het oude Triadegebouw: diabetesverpleegkundigen, diëtisten, podotherapeut, internisten, bloedafnamepunt, fundusfotografie, en de wetenschappelijk onderzoekers……

Gestational diabetes mellitus: diagnosis and outcome

Gestational diabetes mellitus: diagnosis and outcome.
Need for a revision of the Dutch perspective?
PhD ceremony: S.H. Koning, MSc
When: November 27, 2017
Start: 14:30
Promotors: prof. dr. B.H.R. (Bruce) Wolffenbuttel, P.P. van den Berg
Where: Academy building RUG, open to the public
Faculty: Medical Sciences / UMCG

 

Untreated gestational diabetes mellitus (GDM) is associated with an increased risk of complications for both mother and child. Many of these complications can be reduced by early diagnosis and treatment of GDM. However, worldwide there is a lack of agreement on the best way to diagnose and treat GDM.

In the Netherlands, the Dutch Society of Obstetrics and Gynaecology guideline “Diabetes and Pregnancy” for the screening and treatment of GDM was implemented in 2010. The diagnostic thresholds are based on the old WHO consensus originating from 1999 and have until now not been updated to the newest (more stringent) criteria, implemented in 2013. These new criteria have been adopted by many expert committees. However, evidence that applying the stricter criteria for GDM improves pregnancy outcomes is limited.

The research described in this thesis aimed to evaluate the current Dutch national guideline of GDM i.e. what is the outcome of GDM pregnancies using this guideline? And what are consequences when the current diagnostic criteria of GDM are to be revised?

In this thesis we have shown that the currently used national guideline for screening and treatment of GDM is successful in reducing the risk of short-term adverse outcomes, but not in reducing the likelihood of having a large-for-gestational-age neonate. We have also shown that the long-term care for GDM is far from optimal and requires further improvement. In order to further optimize GDM care and pregnancy outcomes we advise the use of more stringent blood glucose criteria for GDM diagnosis.

 

Behandeling met GLP1-receptor agonist kosten-effectief

ScreenHunter_248 Jul. 04 16.12

The cost-effectiveness of exenatide twice daily (BID) versus insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes
Authors: J. Gordon, P. McEwan, U. Sabale, B. Kartman & B.H.R Wolffenbuttel
DOI:10.1080/13696998.2016.1208207

Abstract
Objective: To evaluate the cost-effectiveness of exenatide twice daily (BID) versus bolus insulin lispro three times daily (TID) as add-on therapy when glycemic control is suboptimal with titrated basal insulin glargine and metformin.
Methods: The analysis was based on the recent 4B Study, which compared exenatide BID and lispro TID as add-on therapies in subjects with type 2 diabetes insufficiently controlled despite titrated insulin glargine. The Cardiff Diabetes Model was used to simulate patient costs and health benefits beyond the 4B Study. The Swedish healthcare perspective was adopted for this analysis; costs are reported in €EUR to aid interpretation. The main outcome measure was the cost per quality-adjusted life-year (QALY) gained with exenatide BID compared to lispro TID.
Results: Exenatide BID was associated with an incremental cost of €1,270 and a QALY increase of +0.64 compared with lispro TID over 40 years. The cost per QALY gained with exenatide BID compared with lispro TID was €1,971, which is within conventional limits of cost-effectiveness. Cost-effectiveness results were generally robust to alternative assumptions and values for key model parameters.
Limitations: Extrapolation of trial data over the longer term can be influenced by modelling and parameter uncertainty. Cost-effectiveness results were generally insensitive to alternative values of key model input parameters and across scenarios.
Conclusions: The addition of exenatide BID rather than insulin lispro to basal insulin is associated with similar or better clinical outcomes. Illustrated from the Swedish healthcare perspective, analysis with the Cardiff Diabetes Model demonstrated that exenatide BID represents a cost-effective treatment alternative to lispro TID as add-on therapy in type 2 diabetes patients insufficiently controlled on basal insulin.

Bron: http://www.tandfonline.com/doi/abs/10.1080/13696998.2016.1208207

 

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close